Intelesens develops and manufactures a range of wireless healthcare solutions including its own products and also products for other original equipment manufacturers (OEMs). The company business model is very flexible and includes design, design and manufacture and licensing.
The company originally worked in the design and manufacture of high performance sensors and electrodes. This expertise is based largely on the company's three founding professors who have widely published in this field. Their sensors have been used in monitoring for space missions and their technology is licensed to many of the large medical sensor companies throughout the world.
Today, our focus is on developing technology that enables the early detection of potentially life threatening arrhythmias and respiratory depression. Our Zensor and Aingeal devices provide a continuum of patient coverage from pre-hospital screening, to outpatient clinics, in-hospital ambulatory monitoring and post discharge surveillance. They facilitate the redesign of service provision and provide peace of mind to both patients and clinicians.
Zensor – Wi-Fi enabled, remote monitoring of 3-lead ECG, respiration waveform, rate and activity monitoring.
Aingeal – Wi-Fi enabled, 24 bed surveillance of ECG, respiration waveform and rate, skin temperature, activity and the option of SpO2 measurement.
Bespoke Electrodes - both Zensor and Aingeal benefit from electrodes designed to maximise signal detection, reduce motion artefact and are exclusively manufactured to maximise the capability of each device.
Algorithms – Our proprietary algorithms, harness the expertise of our team of World-class engineers. Our algorithms push forward the boundaries of automatic event detection sensitivity without compromising on striving to minimise the number of false positive events reported, thereby reducing the inherent danger of ‘alarm fatigue’
As Intelesens CTO, Professor John Anderson led advanced product development in the company since 2000. His vision and ingenuity were key in contributing to the development of Intelesens's range of revolutionary, innovative, wearable, wireless monitors, which today hold the promise of revolutionising both acute and chronic healthcare during the next decade. Much of the IP embedded in this ground breaking, novel work has been captured within the company's rich portfolio of patents. Tragically, John died as the result of a short illness in April 2012, however he had provided the business with a rich legacy in electrophysiology which today remains a key feature of the company's technological edge, putting it at the forefront of this exciting and emerging key sector within healthcare. He was succeeded in the CTO role in 2012 by his co-founder and business and academic colleague, Professor Jim McLaughlin.
John held a M Phil and D Phil in BioEngineering and was granted a Personal Chair in Medical Electronics in 1990. He was Head of Engineering School at the University of Ulster in Northern Ireland, Head of BioEngineering at the Royal Victoria Hospital in Belfast and Founder and Director of the Northern Ireland Bio-Engineering Centre. In 1994 he was made a founding Fellow of tpressihe Biological Engineering Society. He published over 300 papers in the field of bioengineering research and holds more than 20 patents in the field.
During the 1960's, John was responsible for the development of the world's first truly portable defibrillator designed for use outside of the hospital. It is estimated that this innovation has already saved many thousands of lives across the globe and will continue to do so. Also an astute businessman, John created a number of companies all providing leading-edge medical products in the areas of defibrillators, body surface mapping, implantable atrial defibrillation and remote vital signs monitoring.
Intelesens naturally broadened into designing the actual monitoring systems and now its market-leading Wireless Vital Signs Platform forms the basis of many OEM products. The benefits and cost savings of wireless monitoring are widely agreed with Intelesens poised to take advantage of this growing market.
With its continued excellent links into a number of world-leading research institutes, Intelesens has an established IP pipeline of new products innovations.
Prof McLaughlin, a physicist is a Fellow of the Institute of Physics and the Irish Academy of Engineering. He has developed significant initiatives within research, technology transfer, outreach and teaching since 1986. Presently, as a Professor in the School of Engineering he is also the Director of the Engineering Research Institute and Director of NIBEC. His salient disciplines address Connected Health, nanotechnology and related bio-sensing applications. He was recently awarded an OBE for his services to Research and Economic Development in Northern Ireland.
He has attained in excess of three hundred publications (H index 28) and he has been honored as an invited speaker at over thirty International Conferences and he has attracted over £42m of funding.
In recent years Professor McLaughlin's over-arching strategy is to develop a strong Connected Health Platform within Northern Ireland (as Chair of the European Connected Health Campus) and the EU. This work involves linking bioengineering and computing sciences with sensor technology developed within NIBEC and thus facilitating clinically-led research initiatives to benefit the healthcare sector. He has recently set up a Connected Health Innovation Centre.
A holder of over twenty patents, including one for the world's best-selling disposable medical electrode, he has successfully co-founded a set of spin-out companies including the highly successful connected health company - Intelesens Ltd. and more recently SiSaF Ltd. He has acted as a consultant associated with key processes and patents associated with Heartscape and Heartsine. Professor McLaughlin has held positions on committees such as: RAE 2008 Materials Assessment Panel; a Matrix Panel chair; EPSRC College; NanoIreland Task Force/Chaired the Nanomaterials Panel; Advisory panel to MSSI; Chair and co-founder of European Connected Health Campus and co-chair of the NI Life and Health Sciences Strategy Panel.
Professor McAdams is widely recognised as one of the world's leading specialists on the linear and non-linear electrical properties of materials and interfaces and on sensor / electrode design. He has published widely on these topics and has over 150 publications and has been involved in the development of electrode systems for several space programmes.
With John Anderson and Jim McLaughlin, Eric founded Sensor Technologies and Devices in 2001, later to become Intelesens, where he remained as Director and Head of Sensor and Electrodes design until 2008.
Eric started and managed the Medical Electrodes Group at NIBEC at the University of Ulster. As well as being a Professor in the School of Electrical and Mechanical Engineering at the University of Ulster, he is Director of the Biomedical and Environmental Sensor Technology (BEST) Centre at UU, linking industry and academic laboratories throughout Ireland.
Eric’s Research roles began in 1980 at Leeds General Infirmary’s Department of Medical Physics.
From 1984 to 1986 he worked in the Department of Clinical Physics and Bio-Engineering at Guys Hospital, London, as a Medical Physicist (Research and Engineering Medical Systems).
From 1986 to 2008 Eric was based at the Nanotechnology and Integrated BioEngineering Centre (NIBEC), University of Ulster in Northern Ireland as Head of the "Medical Sensors" research group.
Since 2008, Eric has led the Biomedical Sensors team at the Health Department of the Institute of Nanotechnologies de Lyon (INL) at INSA, Lyon, France.